(firstQuint)Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain.

 This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-control treatment of twelve weeks.

 During the double-blind treatment period, this study will evaluate the analgesic effect of NKTR-181 versus placebo in patients with moderate to severe chronic low back pain.

.

 Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain@highlight

The purpose of this study is to determine whether a new opioid molecule, NKTR-181, is effective for the relief of moderate to severe chronic low back pain as compared to a placebo.

